C25.1

Malignant neoplasm of body of pancreas

Malignant neoplasm of the body of the pancreas refers to a primary cancerous growth located in the mid-section of the pancreas, situated between the pancreatic head and tail. Histologically, the vast majority of these cases are pancreatic ductal adenocarcinomas (PDAC). Unlike tumors in the pancreatic head, which frequently cause early symptoms such as obstructive jaundice due to their proximity to the common bile duct, tumors in the body are often clinically silent during their early stages. Consequently, they are frequently diagnosed at an advanced stage when the tumor has already invaded local vascular structures—such as the splenic artery, celiac axis, or superior mesenteric artery—or has metastasized to regional lymph nodes or distant organs like the liver. Treatment typically involves a combination of surgical resection (distal pancreatectomy with splenectomy) for localized disease and systemic chemotherapy for advanced or metastatic cases.

Clinical Symptoms

Dull, persistent epigastric or mid-abdominal pain often radiating to the mid-back
Unintentional and significant weight loss
Anorexia and loss of appetite
New-onset or rapidly worsening type 2 diabetes mellitus (Type 3c)
Nausea and dyspepsia
Fatigue and generalized malaise
Splenomegaly resulting from splenic vein compression or thrombosis
Trousseau sign (migratory thrombophlebitis)
Hepatomegaly in the presence of metastatic spread
Palpable abdominal mass in advanced stages

Common Causes

Somatic mutations in the KRAS oncogene (present in >90% of cases)
Inactivation of tumor suppressor genes including CDKN2A, TP53, and SMAD4
Tobacco smoking, which is the most established environmental risk factor
Chronic pancreatitis, particularly of long-standing duration
Long-standing type 2 diabetes mellitus
Obesity and high body mass index (BMI)
Germline mutations in BRCA1, BRCA2, or PALB2 genes
Hereditary syndromes such as Peutz-Jeghers syndrome, Lynch syndrome, and Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome
Family history of pancreatic adenocarcinoma in first-degree relatives
Heavy alcohol consumption leading to chronic pancreatic inflammation

Documentation & Coding Tips

Specify anatomical location within the pancreas precisely.

Example: A 67-year-old patient presents with a 3.5 cm mass confirmed via CT scan located strictly in the body of the pancreas. The pathology report confirms invasive ductal adenocarcinoma of the pancreatic body. This documentation supports C25.1 as the primary diagnosis and impacts HCC 11 for risk adjustment, reflecting the high severity of illness.

Billing Focus: Anatomical site specificity to distinguish from head (C25.0) or tail (C25.2).

Document the presence of associated functional complications such as exocrine insufficiency.

Example: The patient with malignant neoplasm of the body of the pancreas (C25.1) is now experiencing significant exocrine pancreatic insufficiency, manifested by steatorrhea and weight loss. I am initiating Pancrelipase 24,000 units with each meal. This documentation captures the secondary condition K90.3, which increases the clinical complexity profile.

Billing Focus: Inclusion of manifestation codes or secondary codes like K90.3 (Pancreatic steatorrhea).

Clearly link any secondary diabetes to the pancreatic malignancy.

Example: Patient has developed secondary diabetes mellitus due to the destruction of islet cells by the malignant neoplasm of the body of the pancreas. Blood glucose is currently managed with basal insulin. Documentation of E13.9 (Other specified diabetes mellitus) alongside C25.1 accurately reflects the patient's metabolic status.

Billing Focus: Specific coding for secondary diabetes (E13 category) rather than primary Type 1 or Type 2.

Record the status of metastatic spread to secondary sites.

Example: Advanced malignant neoplasm of the body of the pancreas with evidence of secondary malignant neoplasm of the liver and peritoneum. The patient is undergoing palliative chemotherapy for Stage IV disease. Coding includes C25.1, C78.7 (Liver), and C78.6 (Retroperitoneum/Peritoneum).

Billing Focus: Reporting of all active metastatic sites using C78 and C79 series codes.

Detail the specific treatment intent and plan for the encounter.

Example: Encounter for management of malignant neoplasm of the body of the pancreas. Patient is seen today for the second cycle of FOLFIRINOX. The treatment is palliative in nature due to the proximity of the tumor to the celiac axis, precluding resection. Documentation supports high-level MDM for treatment planning.

Billing Focus: Clear documentation of treatment type (chemotherapy, radiation, or surgical planning).

Relevant CPT Codes

99215 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a high level of medical decision making or the physician or other qualified health care professional spends 40-54 minutes of total time on the date of the encounter.
Pancreatic cancer management involves high-complexity decision making regarding chemotherapy, surgical options, and end-of-life care.
48140 - Pancreatectomy, distal subtotal, with or without splenectomy; without pancreaticojejunostomy
The standard surgical procedure for a malignant neoplasm located in the body of the pancreas.
43238 - Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), esophagus, stomach, and/or duodenum
Primary diagnostic procedure to obtain tissue from a mass in the body of the pancreas.
99205 - Office or other outpatient visit for the evaluation and management of a new patient, which requires a high level of medical decision making or the physician or other qualified health care professional spends 60-74 minutes of total time on the date of the encounter.
Initial consultation for a newly diagnosed pancreatic malignancy requires extensive review of imaging and pathology.
74177 - Computed tomography, abdomen and pelvis; with contrast material(s)
Essential imaging for the staging and monitoring of pancreatic body neoplasms.
96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
Standard treatment for both resectable (neoadjuvant/adjuvant) and non-resectable pancreatic cancer.
48146 - Pancreatectomy, distal subtotal, with or without splenectomy; with pancreaticojejunostomy
A variant of the distal pancreatectomy used when reconstruction with the jejunum is necessary.
99214 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a moderate level of medical decision making or the physician or other qualified health care professional spends 30-39 minutes of total time on the date of the encounter.
Used for routine follow-up during chemotherapy where disease is stable and management is moderately complex.
49322 - Laparoscopy, surgical; with aspiration of cavity or cyst (eg, ovarian cyst) (single or multiple)
Often used as a diagnostic laparoscopy to rule out occult peritoneal spread before major surgery.
38571 - Laparoscopy, surgical; with bilateral total pelvic lymphadenectomy
Part of staging procedures to evaluate for nodal involvement.